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The Experts Speak:
A New Feature in the JICR
Michael Gale, Jr,1 Ram Savan,1 Adolfo Garcia-Sastre,2 Ludmila Prokunina-Olsson,3
Kuppusamy Balamurugan,4 and Howard A. Young4
This month we launch a new feature in the JICR: The
Experts Speak. This feature is designed to provide first-hand
insight from topical experts in the fields of interferon, cy-
tokines, innate immunity, and adaptive immune actions of
cytokine biology in disease. We start by asking experts to




Interferon and Innate Immunity Can Control
SARS-CoV-2 Infection, but How Do They Work?
At this point in the SARS-CoV-2 pandemic, we have
learned that approximately 75–85% of people infected with
the virus develop either an asymptomatic infection or mild
to moderate COVID-19 (the disease linked with SARS-
CoV-2 infection) with recovery, while it is a minority of
infected people who develop severe disease or disease
leading to death. However, the sheer number of people in-
fected with SARS-CoV-2 locally and world-wide under-
score the severity of the pandemic. Moreover, ‘‘COVID-19
long haulers’’ who display varied disease symptoms long
after viral clearance present a growing concern to the con-
tinued public health impact of SARS-CoV-2. Types I and III
interferon (IFN) are essential for defense against virus in-
fection, and they can clearly impart suppression of SARS-
CoV-2 infection when administered to cultured cells prior to
virus infection. SARS-CoV-2 encodes multiple proteins
than can antagonize innate immune programs of the infected
cell, including proteins that suppress IFN signaling and ef-
fector actions such that when administered after infection
IFN is not effective to suppress viral replication. When
clinically administered as a therapeutic to infected hospi-
talized patients, it is clear that early treatment with IFN can
be beneficial and reduce inpatient time to recovery. IFN
actions are mediated by interferon-stimulated genes (ISGs),
the main effectors that directly suppress virus replication
and/or serve to regulate cell metabolism and program the
adaptive immune response for clearing infection. IFN ac-
tions can also impart cell death, thus limiting virus expan-
sion across tissues. What are the genes that mediate these
actions? Recently, genome-wide association studies (GWAS)
aimed at defining genes that link with control or susceptibility to
SARS-CoV-2 infection have identified IFN response signaling
and ISGs as essential factors of innate immune defense against
infection, including Ifnar1 (type I IFN receptor subunit), Tyk2
(protein kinase of the Jak-STAT pathway of IFN signaling), and
Oas1 (an ISG with known antiviral and immune-modulatory
activities). Furthermore, autoantibodies against type I IFNs also
strongly associate with severe COVID-19 disease. These stud-
ies indicate that IFN and specific ISGs are paramount for de-
fense against SARS-CoV-2 wherein their activities are
important for the early control of infection and disease. IFN
limits cell to cell, tissue, and systemic spread of virus through
autocrine and paracrine actions to induce ISGs and antiviral
activity in infected cells and importantly in bystander cells.
Beyond a few ISGs we know little of what ISGs control SARS-
CoV-2 infection nor do we know how IFN impacts infection in
the many different tissues implicated in COVID-19 and sys-
temic disease severity. How is it that most people control in-
fection and are asymptomatic or only progress to mild COVID-
19 and recovery? Research to address this question should focus
on understanding IFN and ISG actions in innate immunity to
infection. Findings in this area could lead to development of
revised or novel therapeutic regimen that direct ISG actions to
clear infection and protect against COVID-19.
Michael Gale, Jr.
Ram Savan
University of Washington School of Medicine
Seattle, WA
USA
1University of Washington School of Medicine, Seattle, Washington, USA.
2Icahn School of Medicine at Mount Sinai, New York, New York, USA.
3National Cancer Institute, Rockville, Maryland, USA.
4National Cancer Institute, Frederick, Maryland, USA.
*Correction added on October 20, 2021 after first online publication of May 17, 2021: The fourth author name has been corrected
from Ludmila Prokunina-Olsso to Ludmila Prokunina-Olsson.
JOURNAL OF INTERFERON & CYTOKINE RESEARCH
Volume 41, Number 5, 2021
ª Mary Ann Liebert, Inc.
DOI: 10.1089/jir.2021.29021.exp
161
Type I/III IFN and SARS-CoV-2:
More Research Is Needed
While SARS-CoV-2 encodes multiple mechanisms that
reduce type I/III IFN induction as well as type I/III IFN
signaling, pretreatment of cells and animals with type I/III
IFN inhibits virus replication. This opens the possibility to
use type I/III IFNs for the treatment of SARS-CoV-2 in-
fections. However, one should consider that type I IFN
treatment, especially after infection, might increase disease
severity due to its pro-inflammatory properties. In this re-
spect, type III IFN, signaling mainly only in epithelial cells
due to the tissue and cell type restriction of its receptor,
might offer a safer alternative for the therapeutic treatment
of SARS-CoV-2 infections. In any case, such a treatment
has better chances to be effective given very early after
infection or as a prophylactic, especially if administered
locally to the respiratory tract. In any case, more research is
needed on how to exploit the potent antiviral properties of
IFNs for the treatment of viral infections without unwanted
local and systemic side effects.
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One Less Problem with IFN Therapy
for COVID-19: It Will Not Induce ACE2
Expression and Increase Infection
Mitigation of COVID-19 using IFN therapies could be
preventive or early post-exposure and possibly topical, re-
stricted to the respiratory tract. In addition to the direct
antiviral effect, the goal of this intervention is to prevent
progression to more severe disease, such as by preserving
ACE2 on the cell surface. In addition to being a SARS-
CoV-2 receptor, ACE2 is an important factor in the renin-
angiotensin system and its deficit due to co-internalization
with the virus may aggravate disease conditions. However,
ACE2 induction, not deficit, was one of the early concerns
related to IFN-based therapy for COVID-19. It has been
proposed that ACE2 is an interferon-stimulated gene (ISG)
induced by both the virus and endogenous or exogenous
IFNs. Thus, it was speculated that IFN treatment would
induce ACE2 expression and increase viral uptake (Ziegler
et al. 2020). We (Onabajo et al. 2020) and two other groups
(Ng et al. 2020; Blume et al. 2021) showed that a novel
truncated transcript, which we designated as delta ACE2
(dACE2) is an ISG induced by IFNs and viruses. Previous
analyses were based on measuring the combined expression
of ACE2 and dACE2 and thus were misleading. However,
dACE2 lacks half of the N-terminal domain necessary for
interaction with the viral spike protein and does not appear
to bind the virus. Thus, IFN-driven induction of dACE2 was
not increasing the viral uptake in vitro. On the other hand,
ACE2 acts as a viral receptor but is not an ISG. What does
this finding mean for SARS-CoV-2 infection and possible
COVID-19 treatment with IFNs? In the absence of ACE2
induction, enhanced viral uptake is one less problem to
worry about when considering possible side effects of using
IFN-based therapy for COVID-19.
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Interferon Therapy for SARS-CoV-2:
Is It Underappreciated?
SARS-CoV-2, a large family of coronaviruses, impacts
worldwide population health and it is imperative to design new
strategies and treatment options to combat this pandemic. The
pathogenicity of SARS-CoV-2 is due to immune evasion that
includes inactivation of antiviral and immunomodulatory genes
such as interferons at the early stages mediated by viral proteins
(Lei et al. 2020; Xia et al. 2020). Despite the fact that type I and
type III interferons (IFNs) are used in the treatment of multiple
viral infections, it is critical that the outcome of the use of
interferons will depend on the study models and the study
conditions (Lei et al. 2020; Xia et al. 2020). Accumulating ev-
idence suggests that type I or type III IFNs can reduce SARS-
CoV-2 infection if used early in infection, thus providing proof
of principle that type I or type III IFNs can be utilized in com-
bination therapy as potential antiviral treatments (Vanderheiden
et al. 2020; Felgenhauer et al. 2020; Zhou et al. 2020). Along
these lines, an open-label randomized controlled clinical trial is
now underway for the treatment of SARS-CoV-2 with re-
purposing the antiviral benefits of the FDA-approved drug
Remdesivir along with the immunomodulator interferon 1 beta
(NCT04647695). The use of interferon beta is important as
some patients have been found to express anti-type 1 interferon
antibodies but these antibodies do not neutralize interferon beta
(Bastrad et al. 2020). The presence of these autoantibodies also
raises the possibility and type III interferons may have a true
clinical benefit and initial trials with type III interferons are
underway (NCT04534673; NCT04342976; NCT04354259;
NCT04388709). However, many questions need to be an-
swered: a) whether the type I and type III IFNs along with other
antiviral drugs such as Remdesivir can boost immune responses
against all the new variants of SARS-CoV-2; b) whether the
delayed interferon responses are indeed a benefit for the host or
contribute to a severe cytokine storm; c) can the use of interferon
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enhance immunity to future infections and/or alter the response
to the vaccines? and d) would widespread use of inhaled/nasal
drop interferons be realistic and be practical for many countries
and lessen disease severity in countries where immunization
rates are low? Currently, the pilot studies and initial observa-
tions suggest that in addition to the newly developed vaccines,
interferon therapy may bring much more hope to combat this
global public health threat.
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